Peter Tsvetkov
About Peter Tsvetkov
Peter Tsvetkov is a research scientist and group leader at the Broad Institute of MIT and Harvard, where he has worked since 2021. His research focuses on cancer cell resistance mechanisms, utilizing high throughput drug screens and CRISPR/Cas9 technology.
Work at Broad Institute
Peter Tsvetkov has been a Research Scientist and Group Leader at the Broad Institute of MIT and Harvard since 2021. In this role, he leads research initiatives focused on cancer biology and drug resistance mechanisms. Prior to his current position, he worked as a Research Scientist II at the same institute from 2019 to 2021. His work at Broad has involved implementing high throughput small molecule drug screens and whole genome CRISPR/Cas9 deletion screens.
Previous Research Experience
Before joining the Broad Institute, Peter Tsvetkov served as a Postdoctoral Fellow at the Whitehead Institute from 2012 to 2017. He also held a Postdoctoral Fellow position at the Broad Institute from 2018 to 2019. Earlier in his career, he completed a postdoctoral fellowship at the Weizmann Institute of Science from 2011 to 2012. These roles contributed to his extensive background in biochemistry and molecular biology.
Education and Expertise
Peter Tsvetkov earned his Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology from the Weizmann Institute of Science, where he studied from 2005 to 2010. He also obtained a Master of Arts (M.A.) in the same field from the Weizmann Institute from 2002 to 2004. Earlier, he completed a Bachelor of Applied Science (B.A.Sc.) in Physics and Biology at Tel Aviv University from 1998 to 2001.
Research Contributions
Peter Tsvetkov's research has revealed fundamental evolutionary conserved mechanisms by which cells develop resistance to proteasome inhibitors. He has suggested experimental strategies to mitigate proteasome inhibitor resistance in cancer. His work includes the implementation of high throughput drug screening techniques to better understand cancer cell resistance mechanisms.